- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Tetra Bio-Pharma Adds Veterinary Oncologist To Advisory Board
Tetra Bio-Pharma incorporated Dr. Louis-Philippe de Lorimier into their clinical advisory board for the veterinary market.
Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) incorporated Dr. Louis-Philippe de Lorimier into their clinical advisory board for the veterinary market.
As quoted in the press release:
“We are leveraging our current R&D work in humans to accelerate the development of the first cannabinoid-based drug for pets in the cancer-associated supportive therapy market, including pain. This market is underserved and patients and their owner are waiting for alternatives that are safer, more tolerable and more efficacious. We believe that our collaboration with Dr. de Lorimier will bring significant contributions to the launch of the first Health Canada approved drug for pets using cannabinoid-based active ingredients,” states Dr. Guy Chamberland, Chief Scientific Officer (CSO) of Tetra.
Once approved, the trial will be run at private veterinary clinics across Canada, which treats tens of thousands of animals every year.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.